Method for preparing fraction 4 (apd-f4) and fraction 5 (apd-f5) adaptogenic dorogov's preparation

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and particularly to preparations for a therapy of oncological diseases, treatment of allergy, prevention and health improvement. The invention represents a method for preparing fraction 4 (ADP-f4) and fraction (ADP-f5) adaptogenic Dorogov's preparations, characterised by the fact that a primary product is a fraction 2 antiseptic Dorogov's stimulator (ADP-f2) to be thermally treated.

EFFECT: implementing the given invention provides the more effective prevention and eliciting anti-stress reactions for the purpose of improving the functional state of organism and increasing a resistance in an activation therapy.

2 tbl

 

The invention relates to medicine and, in particular drugs for the treatment of neoplastic diseases, Allergy treatment, prevention and overall health of the person.

It is known that in many pathological processes is the development of chronic stress. In addition, such a basis can be and preactivate, and anti-stress reaction low and very low levels of reactivity. The removal of the body of these adverse conditions is the method of activation therapy.

Activation therapy shows almost everything, one for healing and prevention, the other for treatment, either independently or in conjunction with a variety of therapies and surgical interventions. Activation therapy shown to protect against the damaging action of factors of any nature, big loads, both physical and emotional, as well as to slow down aging. To invoke the desired anti-stress reactions to improve the functional state of the organism and the rise of resistance upon activation therapy currently uses a variety of biostimulants of plant and animal origin, neurotropic substances.

Known drug DCA (antiseptic stimulant Dorogov) - product dry sublimation of meat and bone meal. Sublimation fabrics ka the method provides a gradual decomposition of organic substances (proteins, fats, carbohydrates, nucleic acids) to low molecular weight components, which by their structure is similar to the metabolites of cellular metabolism and, therefore, inherent in the living organism [Deryabina SI, Nikolaev A.V. Chemical farmakologicheskaya of product characteristics ASD. // Proceedings of all-Union Institute of experimental veterinary medicine. - 1968. Volume XXXV. - Moscow]. When receiving per os they are not exposed to the action of proteolytic enzymes and are absorbed into the bloodstream unchanged, so the drug has neither the species nor histological specificity of the antigenic properties and the cumulative effect is absent.

Known drug DCA fraction 2(ASD-f2) is a transparent volatile liquid, of a peculiar pungent smell, yellow or yellow-red color, soluble in water, pH 8.5 to 9.5. Density at 20°C was 1.04. LD for white mice 1473 ml/kg

Known drug DCA fraction 3(ASD-f3) is a thick liquid black color, a distinctive smell, soluble in alcohol, animal and vegetable fats, mineral oils and insoluble in water. Density at 15°C - 0,913-0,990.

The drug ASD, the universal adaptogen, affects almost all parts of the protection of a living organism. Its main normalizing effect mediated through the high system of protection of the Central nervous system(CNS), the autonomic nervous system and neurohumoral regulation. Sequentially activating the endocrine and immune system. ASD prevents or reduces the suppressive effect of glucocorticoids inhibits suppression thymicolymphatic system and, thereby, prevents the development of immunopathy under stress. In the tissues the drug is being implemented through activatio of a number of enzyme systems(acetylcholine - acetylcholinesterase, Na, K-ATPase, RNase, thiol enzymes).

In medicine drugs ASD successfully used for the treatment of skin diseases, hypertension, asthma, diseases of the gastrointestinal tract (GIT), purulent septic diseases, neuritis, neuralgia, tuberculosis and malignant neoplastic lesions of the stomach, kidneys, lungs, genitals, blood in dental practice. [RF patent №2159116 from 18.04.2000, M. CL. A61K 35/32, A61K 35/34, A61K 35/36, A61P 3/00, A61P 37/00 (prototype)]

However, the drawback of the drug DCA is relatively intense (unpleasant) sharp smell. In the treatment of several conditions, the dose can be quite high (more than 15-20 ml per day), which creates a certain subjective difficulties taking medication.

The aim of the invention is to improve the prevention and the challenge of anti-stress reactions to improve functional with the situation of the body and lifting resistance when the activation therapy.

This goal is achieved by the fact that the original product take antiseptic stimulant Dorogov faction 2 (ASD-f2) obtained by dry sublimation of organic substances, with the mode content of the protein from 44%to 87%, subjecting it to heat treatment without oxygen in the range of 5-7 hours at a temperature of 300°-500°C, volatile fractions condense cooling and defend before the separation into two fractions, followed by the separation of antiseptic stimulant Dorogov faction 2 (ASD-ƒ2), filtered it, and is distilled by heating to from 60°C to 140°C decreasing in volume from 5% to 12% of the original volume and get adaptogenic drug Dorogov fraction 4 (APD-f4) in the form of a thick black mass, odourless pH≤6, which is cooled to 0°C, then slowly heated wasgone in the temperature range of 0°-375°C to obtain a clear liquid dark brown to black in color, with a light smell, and density close to unity, which is the fraction 5(APD-f5), with a slight, barely perceptible odor and a density close to unity, the more soluble 10 grams per 100 grams of solvent, in water and alcohol. The total known criterion of solubility of the substance and measure the solubility of a substance in a saturated solution under certain conditions (temperature, pressure). It is believed that if 100 grams of solvent dissolves more ham substances, it is soluble substance.

The implementation of get adaptogenic preparations fraction 4(APD-f4) and fraction 5 (APD-f5) by dry distillation of organic substances is as follows:

Get adaptogenic drugs Dorogov fraction 4(APD-f4) and fraction 5 (APD-f5) in three, and in two stages.

In the first case, at the preparatory stage produces a dry sublimation of organic substances, such as meat and bone meal, with the mode content of the protein from 44% to 87% (but not less than 44%) subjecting to heat treatment without oxygen in the range of 5-7 hours at a temperature of 300°-500°C. Volatile fractions condense when cooled (natural or artificial) and defend before the separation into two fractions one of which is antiseptic stimulant Dorogov faction 2 (ASD-f2), the other faction is antiseptic stimulant Dorogov fraction 3(ASD-f3)

In the second case, except the first, preparatory phase, the source material comes ready antiseptic stimulant Dorogov faction 2(ASD-f2).

In the second stage, after filtering the liquid fraction 2(ASD-f2) is distilled by heating to from 60°C to 140°C achieving a reduction in the amount of from 5% to 12% of the volume of the original product, and get adaptogenic drug Dorogov fraction 4(APD-f4). The obtained fraction 4(APD-f4) is a thick black m is cel, odorless pH≤6. The smell disappears as a result of chemical reactions of the distillation of high temperature and time of processing.

In the third stage, the basis of the accept fraction obtained 4(APD-f4) which is cooled to 0°C, then slowly heated wasgone in tempera range 0°-375°C., to obtain a clear liquid dark brown to black color, with a slight, barely perceptible odor and a density close to unity, which is the fraction 5(APD-f5), soluble than 10 grams per 100 grams of solvent, in water or alcohol. The total known criterion of solubility of the substance and measure the solubility of a substance in a saturated solution under certain conditions (temperature, pressure). It is believed that if 100 grams of solvent dissolves more than 10 grams of the substance, it is well soluble substance.

Thus adaptogenic drug Dorogov fraction 5(APD-f5) are obtained in the third stage by a gradual thermal cleavage during sublimation fraction 4(APD-f4) from 0° to 375°C to fraction 5(APD-f5), that is obtained by dry distillation and sublimation of organic substances.

Adaptogenic drugs Dorogov fraction 4(APD-f4) and fraction 5(APD-f5), and the method of their derivation have new properties, such as: negligible odor, higher activity in order to reduce the eskers ASD faction 2(ASD-f2), solubility in water and alcohol, as well as significantly expand the range of effective application of the drug DCA-f2 in combination with drugs faction 4(APD-f4) and fraction 5(APD-f5)

The impact on the nervous system adaptogenic drug Dorogov fraction 5(APD-f5)

1). On functional brain activity in animals identified in applying the ADF-f5 strengthening of the excitatory process that prolongs the tension conditional reflex activity and inhibits the extinction of the positive conditioned reflex, which led to the intensification of processes of excitation and inhibition in the Central nervous system(CNS). Used doses of 0.015 ml / kg body weight of the object.

2). The influence of the ADF-f5 subcortical centers, respiratory and vasomotor (increased heart rate and respiration)

3). Unlike the SDA-f2, APD-f5 in concentrations of from 1250 to 1:5000 was not shown descodificador action was observed delegate(extension) souzou heart to 70% of the original.

In experimental myocarditis action APD-f5 was the same.

It has been found that doses from 0,007 to 0,021 ml / kg body weight in mice can cause a decrease in volume of circulating fluid in the body due to the deposition of blood in the vessels of the mesentery and periferica vessels, which leads to rapid reduction of blood pressure (BP).

<> The effect on the vessels of the heart adaptogenic drug Dorogov fraction 4(APD-f4)

When exposed to the vessels of the heart adaptogenic drug Dorogov fraction 4(APD-f4) revealed a mild vasodilator effect to 20-25% of the original (on the isolated heart).On the renal vessels APD-f4 exerts an active influence by expanding blood vessels and activating the filtration capacity of the kidneys. The study of the effects of adaptogenic drug Dorogov fraction 4 (APD-f4) in the level of glucose in the blood of rabbits revealed the following pattern on the SDA-f2 see Table 1.

Table No. 1
The sugar content in mg %%
No. of rabbitsFasting to experienceWithin 1 hour after administration of glucose and medication2 hours after injection of glucose and medicationAfter 3 hours after administration of glucose and medicationNote (g/kg) wet weight
123456
5 131178165116The drug DCA-2 was administered orally at the rate of 0.5 g/kg
610715495105The drug DCA-2 was administered orally at the rate of 0.5 g/kg
8125157119113The drug DCA-2 was administered orally at the rate of 0.5 g/kg
111112276120The drug DCA-2 was administered intravenously at the rate of 0.5 g/kg

123456
310714212896The drug DCA-2 was administered intravenously at the rate of 0.5 g/kg

After 1 hour, the blood sugar has increased by an average of 23 mg % instead of 43 mg % when given glucose.

The following experiments were set on rabbits, which together with glucose was administered APD-f4 and a component of the drug DCA-f2. The drug was administered orally at doses of 1 and 2 g/kg, and intravenous 0.3 and 0.5 g/kg the Results are shown in Table No. 2.

Table No. 2.
No. of rabbitsFasting to experienceWithin 1 hour after administration of glucose and medication2 hours after injection of glucose and medicationAfter 3 hours after administration of glucose and medicationNote(g/kg) wet weight
2387899280The drug APD-f4 was administered orally at a rate of 0.1 g/kg
24838910571The drug APD-f4 was administered orally at a rate of 0.1 g/kg
18111 1198286The drug APD-f4 was administered orally at a rate of 0.1 g/kg
191261029280The drug APD-f4 was administered orally at a rate of 0.1 g/kg
25101117142117The drug APD-f4 was administered orally at a rate of 0.1 g/kg
20958910695The drug APD-f4 was administered intravenously at the rate of 0.3 g/kg
16112125 11286The drug APD-f4 was administered intravenously at the rate of 0.3 g/kg
129129136114100The drug APD-f4 was administered intravenously at the rate of 0.5 g/kg
21809310084The drug APD-f4 were carried out intravenously at the rate of 0.5 g/kg
22751027973The drug APD-f4 was administered intravenously at the rate of 0.5 g/kg

The data show that the fluctuations of sugar were very minor and did not extend beyond the normal blood sugar, as in intravenous and oral administration of the drug.

On the basis of the above experiments we can draw the following conclusions:

1. The drug DCA-f2 entered at once is together with glucose through the mouth to rabbits at a dose of 0.5 g/kg does not have any noticeable effect on the blood sugar of rabbits.

2. The drug DCA-f2, injected at a dose of 0.2 g/kg simultaneously with glucose, reduces the sugar content in the blood of rabbits.

3. The drug APD-f4 introduced rabbits as intravenous and oral together with glucose, significantly reduces the sugar content in the blood of rabbits. The sugar content varies within limits and does not increase, as it was observed in rabbits that were administered one glucose.

Thus adaptogenic drugs Dorogov fraction 4 (APD-f4) and fraction 5 (APD-f5) are obtained by dry distillation and sublimation of organic substances in three and in two stages. At the first preparatory stage produces a dry sublimation of organic substances such as meat and bone meal with the mode content of the protein from 44% to 87% (but not less than 44%) subjecting to heat treatment without oxygen in the range of 5-7 hours at a temperature of 300°-500°C. Volatile fractions condense when cooled (natural or artificial) and defend before the separation into two fractions one of which is antiseptic stimulant Dorogov faction 2 (ASD-f2), and the other faction is antiseptic stimulant Dorogov fraction 3 (ASD-f2). In the second stage, after filtering the liquid faction 2 (ASD-f2) it is distilled by heating from 60°C to 140°C achieving a reduction in the amount of up to 5-12% of the volume of the original product. On o the de get adaptogenic drug Dorogov fraction 4 (APD-f4) in the form of a thick black mass odorless pH≤6. The smell disappears as a result of chemical reactions of the distillation of high temperature and time of processing of raw materials. In the third stage, the basis of the accept fraction obtained 4(APD-f4) which is cooled to 0°C, then slowly heated wasgone in tempera range 0°-375°C to obtain a clear liquid dark brown to black color, with a slight, barely perceptible odor and a density close to unity, soluble in water and alcohol which is the fraction 5 (APD-f5). In addition to the exclusion of the first preparatory stage, when receiving the ADF fraction 4 (APD-f4) and fraction 5 (APD-f5), for the original product may ispolzovatsa ready antiseptic stimulant Dorogov faction 2 (ASD-f2).

The method of obtaining adaptogenic drugs Dorogov fraction 4 (APD-f4) and fraction 5 (APD-f5), characterized in that for the original product take antiseptic stimulant Dorogov faction 2 (ADF-f2)obtained by dry sublimation of organic substances, such as meat and bone meal, with the mode content of the protein from 44%to 87%, subjecting it to heat treatment without oxygen for 5-7 h at a temperature of 300-500°C volatile fractions condense cooling and defend before the separation into two fractions, followed by the separation of antiseptic stimulant Dorogov faction 2 (ASD-f2), filtered it, and is distilled by heating from 60°C to 140°C, the mind is greater in volume from 5 to 12% of the original product, get adaptogenic drug Dorogov fraction 4 (APD-f4) in the form of a thick black mass, odourless pH≤6, which is cooled to 0°C, then slowly heated, wasgone in the temperature range 0-375°C to obtain a clear liquid dark brown to black, with a slight odor and a density close to unity, which is the fraction 5 (APD-f5).



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine and veterinary science and aims at increasing the radioresistance in mammals. In the period of 12 hours to 20-30 minutes before a radiation exposure and immediately thereafter, 0.11% oil preparation of chlorophyll is introduced into the mammals. Linseed oil is used as an oil base. The preparation is introduced in a dose of 11-12 mg/kg intramuscularly.

EFFECT: method enables increasing the radioresistance and survival rate in the mammals.

1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: composition for treating oxidative stress comprises ball-shaped lipoic acid or one of salts thereof, and at least one lipophilic medium. The lipoic acid balls represent particles consisting of an inert core (a nucleus) coated with lipoic acid which is coated with a first layer of an isolating polymer, and with a second polymer layer resistant (stable) at gastric pH. What is also described is a preparation for treating oxidative stress with an unified dose containing the above composition. The preparation is presented in the form of a soft gelatin capsule.

EFFECT: compositions according to the invention are stable in the lipophilic medium.

22 cl, 15 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, particularly toxicology and radiology, to drug preparations based on antioxidant proteins and methods of using them. The pharmaceutical composition for treating toxic conditions wherein the therapeutic effect is ensured by the action of antioxidant, antimicrobial, antitoxic human lacroferrin protein on the human body contains non-replicating nanoparticles of human adenovirus serotype 5 genome with inserted human lactoferrin expressing human lactoferrin in the therapeutically effective amount in the body, and an expression buffer with the particle content not less than 2.33×1011 of physical particles per ml of the expressing buffer. The method of therapy involves administering the composition in the therapeutically effective dose of 7×1011 of physical particles to 7×1013 of physical particles per ml of the expressing buffer per an individual; the composition is administered intravenously.

EFFECT: invention provides the stable therapeutic effect after the single administration of the composition.

17 cl, 14 ex, 4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition for the therapy of acute toxic conditions. The composition for the therapy of acute toxic conditions contains a protein - human lactoferrin, and additionally contains non-replicating nanoparticles with an inserted gene of human lactoferrin, and an expressing buffer in the following proportions per a dose: human lactoferrin 50 to 100 mg; non-replicating nanoparticles - 7×1011 of physical particles; the expressing buffer - the rest, ml. Human lactoferrin is either donor breast milk lactoferrin, or any human lactoferrin.

EFFECT: invention provides fast onset and prolonged antitoxic action.

4 cl, 8 ex, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine and pharmacy and can be applied in production and application of solutions for intravenous introduction in treatment of conditions, associated with endogenous intoxication. Disintoxication solution contains components in the following ratio (wt %): sodium hypochlorite 0.04-0.08, sodium chloride 0.50-1.00, aminoethane sulfonic acid 0.02-1.20.

EFFECT: novel infusion solution is claimed.

4 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely an agent possessing anti-inflammatory action. The agent possessing anti-inflammatory action contains as active ingredient in the form of a complex prepared of a coelomic fluid of sea urchins containing peptides and amino acids at a certain ratio of the ingredients.

EFFECT: agent possesses a manifested anti-inflammatory effect.

2 cl, 2 tbl, 10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to a method for preparing a carbon sorbent with the antibacterial properties, and to the carbon sorbent with the antibacterial properties prepared by this method. The declared method involves impregnation of the carbon hemosorbent granules in an initiator solution in N-vinylpyrrolidone at pH 7.0-7.5 and a residual pressure of 15-20 mm Hg. The hemosorbent : initiator solution in N-vinylpyrrolidone ratio is 1:1.4-2.0. Then the temperature is raised to 65-75°C, kept at that temperature for 0.5-8 hours in an inert medium and washed in water from the residual monomer at room temperature.

EFFECT: carbon sorbent with the antibacterial properties prepared by the specified method represents the round granules, contains polyvinylpyrrolidone in an amount of 4,5-5,5% and is characterised by a specific surface adsorption of less than 50 m2/g and total pore volume of less than 0,30 cm3/g.

2 cl, 2 tbl, 1 dwg, 7 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and aims at treating necrotic ulcers of oral mucosa in patients with multiple myeloma. Luminal-dependent chemiluminescence of oral fluid is conducted to determine fluorescence light sum and maximum flash. If the light sum value is within the range of 1.02 to 6.6 standard units, and the maximum flash value is 0.7 to 2.5 standard units, the toothpaste Lacalut fluor is used 2 times a day and solcoseryl dental adhesive paste 4 times a day after meals and before bedtime to relieve symptoms completely. The light sum value 8.3 to 13.5 standard units and the maximum flash value 3.4 to 4.2 standard units, the toothpaste Colgate total propolis is used 2 times a day and the film preparation Oblecol three times a day to relieve symptoms completely.

EFFECT: use of the invention reduces a length of epithelisation of necrotic ulcers of oral mucosa.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is using water-soluble hybrid macromolecular compounds O-(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionyl-(1→6)-α-D-glucan and polyethylene glycol bis-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-propionate as erythroprotective agents for phenylhydrazine poisoning. It is shown that the course intravenous introduction of the compounds has manifested erythroprotective action.

EFFECT: invention extends the range of agents applicable in integrated therapy of phenylhydrazine poisoning.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly, the use of human lactoferrin apo-form as an antihypoxant and a hypoxia inducible factor-1 alpha stabiliser.

EFFECT: invention provides the use of the natural iron chelator lactoferrin, no toxicity, hypoallergenicity, an ability to penetrate through the bowel into the blood flow and through the blood-brain barrier.

2 tbl, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and medicine, and concerns using 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydroimidazo[4,5-c]quinolin-1-yl)phenyl]propionitrile or 8-(6-methoxypyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethylphenyl)-1,3-dihydroimidazol[4,5-c]quinolin-2-one.

EFFECT: preparing a pharmaceutical formulation for treating a VBGF-stimulated angiogenic disease, a method of treating a VBGF-stimulated angiogenic disease and using the above compounds for the high-efficacy treatment of the above diseases.

5 cl, 4 dwg, 4 ex

FIELD: biotechnologies.

SUBSTANCE: invention refers to a method for obtaining a compound of formula 682, which is in a crystalline form, where the above method involves the following: (i) treatment of the compound of formula 682-9 with palmitic anhydride mixed with H2O/dioxane so that the compound of formula 682 is formed; (ii) treatment of the product obtained at stage (i) with methanol so that the compound of formula 682 is obtained in the form of solvate with methanol (Form K); (iii) extraction of the compound of formula 682, which has been obtained at stage (ii) in the form of solvate with methanol (Form K); (iv) optional cleaning of the product of stage (iii) by recrystallisation. Besides, the invention proposes a method for obtaining the compound of formula 682-4, where the above method involves the following: (i) conversion of the compound of formula 682-1 to the compound of formula 682-2' by treatment of the above compound of formula 682-1 with 1,3-dichloro-1,1,4,4-tetraisopropyldisiloxane (CIPS) in pyridine; (ii) conversion of the above compound of formula 682-2' to the compound of formula 682-3 by treatment of the above compound of formula 682-2' with acetic anhydride to EtOH; and (iii) conversion of the above compound of formula 682-3 to the compound of formula 682-4 by treatment of the above compound of formula 682-3 with an oxidiser, preferably with free radical 2,2,6,6-tetramethylpiperidinyloxy (TEMPO) and NaOCl. Further aspects of the invention refer to use of the above methods for obtaining 2'-cyano-2'-deoxy-N4-palmitoyl-1-β-D-arabinofuranosylcytosine, pyrimidine nucleoside, and are suitable for treatment and/or prevention of cancer.

EFFECT: improvement of compounds.

22 cl, 1 tbl, 1 ex

FIELD: biotechnologies.

SUBSTANCE: invention refers to new purine compounds of formula I and their pharmaceutically acceptable salts that have properties of an inhibitor of lipidic kinases including p110 alpha and other isoforms of PI3K. In formula I , R1 is chosen from H, C1-C12alkyl and -(C1-C12alkene)-(C5-C6 heterocyclyl), where heterocyclyl can contain 1-2 heteroatoms in a cycle, which are chosen from nitrogen, and in which alkyl and heterocyclyl are optionally replaced with one or more groups independently chosen from -NHCOCH3, -NHS(O)2CH3, -OH, -S(O)2N(CH3)2 and -S(O)2CH3; R2 is chosen from C1-C12alkyl, -(C1-C6alkene)-(C5-C6heterocyclyl) or -(C1-C6alkene)-C(=O)-(C5-C6heterocyclyl), in each of which heterocyclyl contains 1-2 heteroatoms chosen from nitrogen and oxygen, -(C1-C6alkene)-(C6aryl), where aryl is chosen from phenyl, and -(C1-C6alkene)-(C5-C6heteroaryl), where heteroaryl contains 1 atom of nitrogen, in which alkyl, heterocyclyl, aryl and heteroaryl are optionally replaced with one or more groups independently chosen from F, Cl, Br, I, CH3, -CF3, -CO2H, -COCH3, -CO2CH3, -CONHCH3, -NHCOCH3, -NH(SO)2CH3, -OH, -OCH3, -S(O)2N(CH3)2 and -S(O)2CH3; and R3 represents monocyclic heteroaryl chosen from derivatives of pyridine and pyrimidine, which are specified in Claim 1 of the invention formula.

EFFECT: applicability of a compound for treatment of proliferative diseases, such as cancer.

7 cl, 2 dwg 1 tbl, 59 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula I

or a pharmaceutically acceptable salt thereof, where R1 is H or R1 and R2 together with a nitrogen group can form where A, B, C and D are independently selected from a group consisting of CR1a and N; where at least one of A, B, C and D is CR1a; where R1a is selected from a group consisting of H, -ORi, -SRii, -S(O)Riii, -C(O)NRvRvi and CF3, where Ri is selected from a group consisting of methyl, ethyl, propyl, hydroxyethyl, hydroxypropyl, 2-oxo-2-phenylethyl, butyl, acetonitrile and benzyl; Rii, Riii and Riv denote methyl; Rv and Rvi are independently selected from a group consisting of H, methyl, ethyl, hydroxyethyl, hydroxypropyl, diethyalminoethyl, phenyl, pyridinyl, methoxyethyl, hydroxyethoxyethyl, benzyl, phenylethyl, 2-hydroxy-1-hydroxymethyl-2-phenylethyl and carbomoylethyl, or Rv and RVi together form morpholine or ethyl ester of piperazine; R2 is selected from a group consisting of phenyl, naphthyl, pyrazolyl and C1-C8alkylene phenyl; R3 is C1-C8alkylene; R4 is selected from a group consisting of H, C1-C8alkyl and -C=NH(NH2). The invention also relates to compounds of formulae I-A

I-B I-C

I-D I-E

values of radicals of which are given in the claim; a method of treating said pathological conditions, a pharmaceutical composition based on said compounds, a method of identifying a Trp-p8 agonist and specific compounds.

EFFECT: obtaining compounds which are useful as Trp-p8 modulators.

25 cl, 19 dwg, 8 tbl, 17 ex

FIELD: biotechnologies.

SUBSTANCE: invention refers to bicyclic heterocycles of formula I and formula II , in which radicals and symbols have values specified in the formula of the invention. These compounds have inhibiting activity in relation to MEK kinase. The invention also refers to a pharmaceutical composition for treatment of hyperproliferation disease or inflammatory disease, to a method for inhibition of abnormal growth of cells or treatment of hyperproliferation disorders and to a treatment method of inflammatory diseases of a mammal. Besides, the invention refers to use of a pharmaceutical composition for preparation of a medicinal agent for treatment of the above diseases of a mammal.

EFFECT: improving compound application efficiency.

19 cl, 29 ex

FIELD: biotechnologies.

SUBSTANCE: invention refers to a compound of formula (I):

,

where R1 represents NR7C(O)R8 or NR9R10; R2 represents hydrogen; R3 represents halogen; R4 represents hydrogen, halogen, cyano, hydroxy, C1-4alkyl, C1-4alkoxy, CF3, OCF3, C1-4alkylthio, S(O)(C1-4alkyl), S(O)2(C1-4alkyl), CO2H or CO2(C1-4alkyl); R5 represents C1-6alkyl (replaced with NR11R12 or heterocyclyl that represents nonaromatic 5-7-membered ring containing 1 or 2 heteroatoms independently chosen from a group containing nitrogen, oxygen or sulphur); R6 represents hydrogen, halogen, hydroxy, C1-4alkoxy, CO2H or C1-6alkyl (possibly replaced with NR15R16 group, morpholinyl or thiomorpholinyl); R7 represents hydrogen; R8 represents C3-6cycloalkyl (possibly replaced with NR24R25 group), phenyl or heteroaryl, which represents aromatic 5- or 6-membered ring containing 1 to 3 heteroatoms independently chosen from the group containing nitrogen, oxygen and sulphur, and which is probably condensed with one 6-membered aromatic or nonaromatic carbocyclic ring or with one 6-membered aromatic heterocyclic ring, where the above 6-membered aromatic heterocyclic ring includes 1 to 3 heteroatoms independently chosen from a group containing nitrogen, oxygen and sulphur; R9 represents hydrogen or C1-6alkyl (possibly replaced with pyrazolyl); R10 represents C1-6alkyl (possibly replaced with phenyl or heteroaryl group, which represents aromatic 5- or 6-membered ring containing 1 or 2 heteroatoms independently chosen from the group containing nitrogen, oxygen or sulphur, and which is possibly condensed with one 6-membered heterocyclic ring, where the above 6-membered aromatic heterocyclic ring contains 1 or 2 heteroatoms independently chosen from the group containing nitrogen, oxygen or sulphur; where the above phenyl and heteroaryl groups in R8, R9 and R10 are possibly independently replaced with the following group: halogen, hydroxy, C(O)R42, C1-6alkyl, C1-6hydroxyalkyl, C1-6halogenoalkyl, C1-6alkoxy(C1-6)alkyl or C3-10cycloalkyl; unless otherwise stated, heterocyclyl is possibly replaced with group of C1-6alkyl, (C1-6alkyl)OH, (C1-6alkyl)C(O)NR51R52 or pyrrolidinyl; R42 represents C1-6alkyl; R12, R15 and R25 independently represent C1-6alkyl (possibly replaced with hydroxy or NR55R56 group); R11, R16, R24, R51, R52, R55 and R56 independently represent hydrogen or C1-6alkyl; or to its pharmaceutically acceptable salts.

EFFECT: new compounds are obtained, which can be used in medicine for treatment of PDE4-mediated disease state.

10 cl, 2 tbl, 202 ex

FIELD: biotechnologies.

SUBSTANCE: pox virus of variolovaccine is proposed, which includes a defect F2L gene and a suicide gene. Pox virus has oncolytic activity. Besides, a reproduction method of such pox virus and its use for treatment of proliferative diseases or diseases with increased activity of osteoclasts is proposed.

EFFECT: improving compound application efficiency.

31 cl, 12 dwg, 3 tbl

FIELD: biotechnologies.

SUBSTANCE: an in vitro generation method of antigen-specific cytotoxic cells with activity against ovarian carcinoma cells is proposed. Simultaneously, a non-adhesive fraction of mononuclear cells (MNC) and mature dendritic cells (DC) are cultivated in presence of recombinant human interleukine-12 and recombinant human interleukine-18. MNC are extracted from peripheral blood of patients having ovarian carcinoma. Mature DC are obtained from monocytes of adhesive MNC fraction after two-day cultivation, and first, activation by lysate of autologous ovarian carcinoma cells, and then maturation of DC loaded with lysate during one day in presence of recombinant human TMF-α (tumor necrosis factor).

EFFECT: use of the invention provides reduction of a stage for obtaining mature DC, in vitro increases cytotoxicity of antigen-specific cytotoxic cells with antitumor activity and provides an immune response via T-helper to type 1 in respect to ovarian carcinoma, which can be used in ovarian carcinoma therapy.

2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology. What is disclosed is a vaccine representing four RNAs coding a prostate-specific antigen (PSA), a prostate-specific membrane antigen (PSMA), a prostate stem cell antigen (PSCA) and a six-transmembrane epithelial antigen of the prostate (STEAP). The vaccine is applicable for treating prostate carcinoma, preferentially neo-adjuvant and/or hormone resistant prostate carcinoma, as well as related diseases or disorders. Using the vaccine and a kit are also disclosed. The invention can be used in medicine.

EFFECT: preparing the vaccine for treating prostate carcinoma.

16 cl, 23 dwg, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a kit for lung cancer cell sensitisation to cisplatin. The declared kit comprises a first composition containing a therapeutically effective amount of sodium metaarsenite, and a second composition containing a therapeutically effective amount of cisplatin. Also, the invention refers to using the therapeutically effective amount of sodium metaarsenite for lung cancer cell sensitisation in a patient treated with cisplatin.

EFFECT: invention provides increasing the therapeutic effectiveness with a reduced risk of side effects.

10 cl, 4 tbl, 3 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary science, namely to obstetrics and gynaecology. A preparation for treating and preventing sub-clinical, clinical, acute and chronic mastitis in farm and domestic animals contains an active substance that is - triphenyl-(3,5-di-tert-butyl-4-hydroxybenzyl)phosphonium bromide and a pharmaceutically acceptable carrier that is Vaseline in ratio 1:2000.

EFFECT: invention provides the higher antimicrobial effectiveness and the lower toxicity of the ointment with the lower concentration of the active substance.

3 tbl, 5 ex

Up!